Home › Calculator › PRRUF Dividend Calculator 2026
PRRUF Dividend DRIP Calculator 2026
4000.00% YieldHealthcareImmutep Ltd · OTC
Price: $0.05 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When PRRUF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your PRRUF snowball 📈
$10,000 in PRRUF → $3.782261557955302e+27M in 10 years · $315,180,768,319,965,300,000,000,000,000,000.00/month
About Immutep Ltd (PRRUF) — Dividend Analysis 2026
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Compare PRRUF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full PRRUF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open PRRUF position with:
🌍 PRRUF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold PRRUF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 4000.00% | 3997.20% | $400,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 3400.00% | 3397.20% | $340,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 3200.00% | 3197.20% | $320,000 / yr |
| 🇬🇧 UK ISA | 0% | 4000.00% | 3997.20% | $400,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 3650.00% | 3647.20% | $365,000 / yr |
| 🇨🇦 TFSA | 0% | 4000.00% | 3997.20% | $400,000 / yr |
| 🇨🇦 CA Taxable | 25% | 3000.00% | 2997.20% | $300,000 / yr |
| 🇦🇺 Super (pension) | 15% | 3400.00% | 3397.20% | $340,000 / yr |
| 🇦🇺 AU Taxable | 30% | 2800.00% | 2797.20% | $280,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2945.00% | 2942.20% | $294,500 / yr |
| 🇫🇷 FR Taxable | 30% | 2800.00% | 2797.20% | $280,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 PRRUF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 PRRUF Dividend Payment Schedule
PRRUF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 PRRUF vs Healthcare Benchmarks
How PRRUF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for PRRUF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ PRRUF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the PRRUF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Immutep Ltd (PRRUF) is currently trading at $0.05, 90% below its 52-week high. The current dividend yield is 4000.00% based on an annual payout of $2.00 per share.
PRRUF (Immutep Ltd) — 4000.00% Dividend Yield Analysis
Immutep Ltd (PRRUF) is a healthcare stock currently trading at $0.05 with a dividend yield of 4000.00%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (4000.00%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.